Brokerages Anticipate Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Will Post Earnings of -$0.49 Per Share

Share on StockTwits

Analysts forecast that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will announce earnings per share (EPS) of ($0.49) for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.41) and the lowest estimate coming in at ($0.55). Crinetics Pharmaceuticals posted earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 28.9%. The business is expected to report its next quarterly earnings results on Tuesday, November 12th.

On average, analysts expect that Crinetics Pharmaceuticals will report full-year earnings of ($1.92) per share for the current year, with EPS estimates ranging from ($2.26) to ($1.59). For the next financial year, analysts expect that the business will report earnings of ($2.56) per share, with EPS estimates ranging from ($2.85) to ($2.03). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.46) by ($0.05). Crinetics Pharmaceuticals had a negative net margin of 1,303.31% and a negative return on equity of 23.45%.

Separately, Zacks Investment Research raised Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 20th.

Shares of Crinetics Pharmaceuticals stock traded up $0.23 on Friday, reaching $18.29. The company’s stock had a trading volume of 21,280 shares, compared to its average volume of 67,542. The company has a market capitalization of $432.11 million and a price-to-earnings ratio of -8.20. The firm’s fifty day simple moving average is $22.31 and its two-hundred day simple moving average is $24.02. Crinetics Pharmaceuticals has a 52 week low of $17.32 and a 52 week high of $42.00. The company has a quick ratio of 18.04, a current ratio of 18.04 and a debt-to-equity ratio of 0.04.

In other news, insider Ventures Iv L.P. 5Am sold 250,000 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $22.20, for a total value of $5,550,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 7.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in CRNX. BNP Paribas Arbitrage SA bought a new stake in Crinetics Pharmaceuticals during the first quarter worth approximately $42,000. Marshall Wace North America L.P. acquired a new stake in Crinetics Pharmaceuticals during the 1st quarter worth about $43,000. JPMorgan Chase & Co. grew its position in Crinetics Pharmaceuticals by 45.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,033 shares of the company’s stock worth $75,000 after purchasing an additional 946 shares during the period. Bank of America Corp DE grew its position in Crinetics Pharmaceuticals by 377.2% during the 4th quarter. Bank of America Corp DE now owns 5,932 shares of the company’s stock worth $179,000 after purchasing an additional 4,689 shares during the period. Finally, TD Asset Management Inc. acquired a new stake in Crinetics Pharmaceuticals during the 2nd quarter worth about $210,000. Hedge funds and other institutional investors own 73.70% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Recommended Story: Liquidity

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.